NASDAQ:RTRX Travere Therapeutics (RTRX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free RTRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.34▼$5.7850-Day Range$24.25▼$28.1852-Week Range$8.98▼$24.96Volume2.78 million shsAverage Volume412,277 shsMarket Capitalization$278.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Travere Therapeutics alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Travere Therapeutics Stock (NASDAQ:RTRX)Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… RTRX Stock News HeadlinesApril 17, 2024 | markets.businessinsider.comCritical Insights From Travere Therapeutics Analyst Ratings: What You Need To KnowFebruary 23, 2024 | realmoney.thestreet.comTravere Therapeutics price target lowered by $3 at H.C. Wainwright, here's whyApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 23, 2024 | msn.comTravere Therapeutics gains as EU backs kidney disease therapyFebruary 21, 2024 | msn.comNew Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?February 17, 2024 | realmoney.thestreet.comTravere Therapeutics price target raised by $4 at Citi, here's whyFebruary 16, 2024 | markets.businessinsider.comTravere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market CompetitionFebruary 14, 2024 | benzinga.comEarnings Preview For Travere TherapeuticsApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.January 11, 2024 | markets.businessinsider.comTravere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market ProspectsDecember 7, 2023 | markets.businessinsider.comOptimistic Outlook for Travere Therapeutics Amid FDA Developments and Strategic ReorganizationDecember 6, 2023 | msn.comTravere (TVTX) Up on Latest Portfolio Updates & ReorganizationDecember 5, 2023 | markets.businessinsider.comBuy Rating for Travere Therapeutics: Optimism Fueled by Regulatory Prospects and Strategic ReorganizationDecember 5, 2023 | realmoney.thestreet.comTravere Therapeutics upgraded to Buy from Neutral at CitiDecember 4, 2023 | marketwatch.comTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU TreatmentsNovember 21, 2023 | benzinga.comTravere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 8, 2023 | markets.businessinsider.comPromising Sales Performance and Growth Prospects Solidify Buy Rating for Travere TherapeuticsNovember 6, 2023 | benzinga.comPreview: Travere Therapeutics's EarningsOctober 31, 2023 | morningstar.comTravere Therapeutics Inc Ordinary Shares TVTXSeptember 30, 2023 | msn.comWedbush Reiterates Travere Therapeutics (TVTX) Outperform RecommendationSeptember 22, 2023 | msn.comWhy Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-LowSeptember 21, 2023 | msn.comWhy Shares of Travere Therapeutics Are Slumping ThursdaySeptember 21, 2023 | markets.businessinsider.comBack To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, ChallengesAugust 31, 2023 | markets.businessinsider.comBank of America Securities Remains a Buy on Travere Therapeutics (TVTX)July 19, 2023 | marketwatch.comMirum Pharmaceuticals to Buy Bile Acid Product Portfolio from Travere TherapeuticsJune 26, 2023 | benzinga.comTVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities LawsMay 3, 2023 | msn.comEvercore ISI Group Maintains Travere Therapeutics (TVTX) Outperform RecommendationSee More Headlines Receive RTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RTRX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879FaxN/AEmployees221Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,430,000.00 Net Margins-49.13% Pretax MarginN/A Return on Equity-36.38% Return on Assets-14.90% Debt Debt-to-Equity Ratio0.66 Current Ratio7.23 Quick Ratio7.14 Sales & Book Value Annual Sales$175.34 million Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book Value$5.15 per share Price / Book1.06Miscellaneous Outstanding Shares51,052,000Free FloatN/AMarket Cap$278.23 million OptionableNot Optionable Beta0.67 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesEric DubePresident, Chief Executive Officer & DirectorLaura M. ClagueChief Financial & Accounting OfficerBill RoteSenior VP, Head-Research & DevelopmentNoah L. RosenbergChief Medical OfficerElizabeth E. ReedSecretary, Senior Vice President & General CounselKey CompetitorsKamadaNASDAQ:KMDANeoleukin TherapeuticsNASDAQ:NLTXErascaNASDAQ:ERASVerrica PharmaceuticalsNASDAQ:VRCAContineum TherapeuticsNASDAQ:CTNMView All Competitors RTRX Stock Analysis - Frequently Asked Questions How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:RTRX) released its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Travere Therapeutics investors own include CVS Health (CVS), Gilead Sciences (GILD), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Novavax (NVAX), Sangamo Therapeutics (SGMO), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK) and Exelixis (EXEL). This page (NASDAQ:RTRX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
